The Pharmacy Times® Diabetes resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Establishing better patient relationships can lead to improved self-management.
Pharmacists can help patients select products and provide education on how to use them.
Investigators have found that although the composition and function the gut microbiome changes throughout the day in most people, these variations stop in patients with type 2 diabetes (T2D).
Although hypoglycemia can be fatal, continuous glucose monitoring may reduce risk.
The rate of weight gain during pregnancy, use of insulin pumps, and CGMS have increased in women with type 1 diabetes, according to new research.
Researchers looked at the effects of a genetic risk score for developing T2D as an adult on metabolism, measured from blood samples taken from participants in the study when they were aged 8, 16, 18, and 25 years.
Being able to predict life expectancy will help care providers decide which A1c target ranges are the best for each patient with diabetes.
Visual impairment confers a tremendous psychosocial burden, yet up to half of atrisk patients skip annual eye examinations. symposium held in conjunction with the Asembia Specialty Pharmacy Summit, noting that up to 17% of cases of blindness can be attributed to diabetic eye disease.
Pharmacy Times spoke with Robert Schumm, MBA, president of Ascensia Diabetes Care, about the challenges that patients with diabetes are facing during the COVID-19 pandemic.
A phase 2 clinical trial demonstrated that a 2-week course of teplizumab was able to delay the onset of clinical type 1 diabetes by 3 years compared with patients taking a placebo.
Using artificial intelligence (AI) and automated monitoring, researchers and physicians at Oregon Health & Science University (OHSU) have designed a method to help people with type 1 diabetes better manage their glucose levels.
Ertugliflozin is a relatively new addition to the SGLT2 inhibitor class of medication.